Trials / Completed
CompletedNCT02437786
Molecular and Cellular Mechanism in Rhinitis Allergic Patients Treated With GRAZAX®
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 58 (actual)
- Sponsor
- ALK-Abelló A/S · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The specific clinical trial is a part in which ALK- Abelló will directly work to explore human immunological mechanisms of SIT (observed after GRAZAX treatment).
Detailed description
The main idea of the project was to address the study of some of the most important inflammatory diseases (psoriasis, rheumatoid arthritis, lupus, rhinitis/asthma… ) with the aim of identifying novel inflammatory markers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GRAZAX | GRAZAX |
Timeline
- Start date
- 2009-09-01
- Primary completion
- 2014-12-01
- Completion
- 2014-12-01
- First posted
- 2015-05-08
- Last updated
- 2018-01-17
Locations
1 site across 1 country: Spain
Source: ClinicalTrials.gov record NCT02437786. Inclusion in this directory is not an endorsement.